Group 1: Elite Pharmaceuticals Inc. (ELTP) - ELTP is a manufacturer of generic drugs, focusing on controlled-release products which require higher manufacturing skills and vertical integration, differentiating itself in a price-sensitive market [2] - The company holds strong positions in the mixed Amphetamine Immediate Release (IR) and Extended Release (ER) markets, with significant growth driven by the ADHD market [3][6] - According to IQVIA data, ELTP commands approximately 20% of the $400 million generic Adderall IR market and 16% of the $800 million Adderall ER market [4] - In Q4 fiscal 2025, total revenues reached approximately $31.9 million, a 78.3% increase from $17.9 million in the previous year, with operating income rising to roughly $11.2 million from $3.7 million [5] - ELTP entered the lisdexamfetamine (Vyvanse generic) market in early 2025, capturing an estimated 8-10% market share despite competition [6] - The company experienced a pull-back in stock price post-earnings due to a $7.2 million warrant charge affecting EPS and increased competition in the ADHD generic space [7][8] Group 2: TSS, Inc. (TSSI) - TSSI's core business includes systems integration, facilities management, and IT procurement services, with a focus on AI-enabled computer racks [12][13] - The company reported a sales growth of 262% to $44 million in recent Q2, raising its 2025 adjusted EBITDA growth guidance from at least 50% to at least 75% [13] - Despite strong growth, TSSI's stock has pulled back nearly 30%, attributed to investor expectations for better leverage and elevated depreciation expenses from facility build-out [14] - TSSI began production at a new 213,000-square-foot facility in Georgetown, TX, optimized for high-volume AI rack integration, with management expecting profitability within a two-year payback period [15] - The stock is currently trading at a trailing EV/Sales multiple of 1.84x, which is reasonable for a business with multi-year sales visibility and proven growth [16][18]

India supplies nearly half the generic drugs Americans consume. America levies no tariffs on them, but that could change before American patents start expiring in the next decade. If handled correctly, India could make America skinny again https://t.co/VtaGPStscRPhoto: Getty Images ...